Development of a cytomegalovirus vaccine lessons from recent clinical trials

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 401-412

  Gonczol, Eva ^a   Plotkin, Stanley ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cytomegalovirus; Protection; Recombinant viruses; Subunit proteins; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

CHEMISTRY; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; HUMAN; IMMUNOLOGY; REVIEW;

CLINICAL TRIALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMAN;

EID: 0035349673     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.401     Document Type: Article

References (77)

1. BRITT WJ, ALFORD CA. Cytomegalovinis. In Virology. Fields BN, Knipe DM, Howley OM et al. (Eds.), lippincottRaven Publishers, Philadelphia, PA (1996)2493-2523.
2. PLOTKIN SA Vaccination against cytomegalovirus, the changeling demon. Pediatr. Infect. Dis. J. (1999) 18313-326.
3. BOPPANA SB, FOWLER KB, BRITT WJ, STAGNO S, PASS RF Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics (1999) 10455-60.
4. STAGNO S, PASS RF, SWORSKY M et a!. Congenital cytomegalovirus infection the relative importance of primary and recurrcmcnt maternal infection. Ar. Engl. J. Med. (1982) 306945-949.
5. FOWLER KB, STAGNO S, PASS RF, BRITT WJ, BOLL TJ, ALFORD CA The outcome of congenital cytomegalovirus infection hi relation to maternal antibody status. N. Engl.J. Med. (1992) 326663-667.
6. SUWANSIRIKUL S, RAO N, DOWLING JN, HO M Primary and seconday cytomegalovirus infection. Arch. Intern. Med. (1977) 1371026-1029.
7. WERNER BG, SNYDMAN DR, FREEMAN R et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients analysis of usage under treatment IND status. Transplant. Proc. (1993) 251441-1443.
8. BOWDEN RA, SAVERS M, FLOURNOY N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl.J. Med. (1986) 3141006-1010.
9. RIDDELL SR, GILBERT MJ, LI C-R, WALTER BA, GREENBERG PD Reconstitution of protective CDS cytotoxic T lymphocyte responses to human cytomegalovirus in unmunodeficient humans by the adoptive transfer of T cell clones. In Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Michelson S, Plotkin SA (Eds.), Eisevier Science Publishers (1993).
10. WALTER EA, GREENBERG PD, GILBERT MJ et al Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl.J. Med. (1995) 3331038-1044.
11. PLOTKIN SA, FURUKAWA T, ZYGRAICH N, HUYGELEN C Candidate cytomegalovirus strain for human vaccination. Infect. Immun. (1975) 12521-527.
12. YAMANE Y, FURUKAWA T, PLOTKIN SA Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine (1983) 123-25.
13. PLOTKIN SA, FARQUHARJ, HORBERGER E Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus./ Infect. Dis. (1976) 134470-475.
14. PLOTKIN SA, HUANG ES Cytomegalovirus vaccine virus (Towne strain) does not induce latency./ Infect. Dis. (1985) 152395-397.
15. PLOTKIN SA, STARR SE, FRIEDMAN HM, GONCZOL E, BRAYMAN K Vaccines for the prevention of human cytomegalovirus infection. Rev. Infect. Dis. (1990) 125827-838.
16. PLOTKIN SA, STARR SE, FRIEDMAN HM et al Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a chellenge.J. Infect. Dis. (1989) 159860-865.
17. PLOTKIN SA, SMILEY ML, FRIEDMAN HM et al Townevaccine-induced prevention of cytomegalovirus disease after renal transplants. lancet(.19&f) 1528-530.
18. PLOTKIN SA, STARR SE, FRIEDMAN HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant a controlled trial. Ann. Intern. Aled. (1991) 114525-531.
19. PLOTKIN SA, HIGGINS R, KURTZ JB Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation (1994) 581176-1178.
20. ADLER SP, STUART ES, PLOTKIN SA et al Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age./ Infect. Dis. (1995) 17126-32.
21. CHA TA, TOM E, KEMBLE G\V, DUKE CM, MOCARSKI ES, PAKTE RR Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. (1996) 7078-83.
22. KEMBLE G, DUKE G, WINTER R, SPAETE R Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids.y. Virol. (1996) 702044-2048.
23. SPAETE RR, CHA TA, LU S, DUKE GM, KEMBLE GW Differences between virulent and avirulent HCMV isoloates. Proceedings of the 23rd International Herpesvims Workshop, York, UK (1998) Abstract #15.
24. DALMONTE P, PIGNATELLI S, MACH M, LANDINI MP The product of human cytomegalovirus (HCMV) UL73 is a new polymorphic structural gyloprotein (gpUL73). J. Human Virol. (In press).
25. BRITT WJ, AUGER D Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res. (1985) 431-36.
26. GYULAI Z, ENDRESZ V, BURIAN K et a!. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IEl-Exon4, gB, pp!50, and pp2S in healthy individuals réévaluation of prevalence of l-specific CTLs.J. Infect. Dis. (2000) 1811537-1546.
27. BRITT WJ, VUGLER L, BUTFILOSKI EJ, STEPHENS EB Cell surface expression of human cytomegalovirus (HCMV) gp55-H6 (gB) use of HCMV-vaccinia recombinant virus infected cells in analysis of the human neutralizing antibody response. J. Virol. (1990) 641079-1085.
28. GONCZOL E, DETAISNE C, HIRKA G el al High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant; the importance of the gB protein in HCMV-immunity. Vaccine (1991) 9631-637.
29. MARSHALL GS, RABALAIS GP, STOUT GG, WALDEYERSL Antibodies to recombinant-dcrivcd glycoprotcin B after natural human cytomcgalovirus infection correlate with neutralizing activity. / Infect. Dis. (1992) 165381-384.
30. SPÄHTE RR A recombinant subunit vaccine approach to HCMV vaccine development. Transplant. Proc. (1991) 2390-96.
31. FREY SE, HARRISON C, PASS RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomcgalovirus glycoprotcin B subunit vaccine./ Infect. Dis. (1999) 1801700-1703.
32. PASS RF, DULIEGE AM, BOPPANA S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotcin B and a new adjuvant. / Infect. Dis. (1999) 180970-975.
33. GONCZOL E, IANACONE J, HO W, STARR S, MEIGNIER B, PLOTKIN SA Isolated gA/gB glycoprotein complex of human cytomcgalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine (1990) 8130-136.
34. QUINNAN GV, KIRMANI N, ROOK AH et al Cytotoxic T cells in cytomegalovirus infection HLA restricted T lymphocyte and non T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow transplant recipients. Ar. Engl. J. Med. (1982) 3077-13-
35. LI CR, GREENBERG PD, GILBERT MJ et al Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant correlation with CMV disease and effect of ganciclovir prophylaxis. B/oorf(1994) 831971-1979.
36. STEFFENS HP, KURTZ S, HOLTAPPELS R, REDDEHASE MJ Preemptive CD8 T-cell immunothcrapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence./ Virol. (1998) 721797-1804.
37. REDDEHASE MJ, MUTTER W, MUNCH K, BUHRING HJ, KOSZINOWSKI UH T lymphocytes specific for murinc cytomegalovirus immediate-early antigens mediate protective immunity./ Virol. (1987) 613102-3108.
38. REDDEHASE MJ The immunogenicity of human and murinc cytomegaloviruses. Ctirr. Op. Immunol. (2000) 12390-396.
39. KOSZINOWSZKI UH, DEL VAL M, REDDEHASE MJ Cellular and molecular basis of the protective immune response to cytomcgalovirus infection. Curr. Top. Microbiol. Immunol (1990) 154189-220.
40. LA ROSSA C, KRISHNAN R, MARKEL S et al Enhanced immune activity of CTL epitope analogues derived from positional scanning synthetic combination libraries. Blood (.In press).
41. ZAIA JA, SISSIONS JGP, RIDDELL S, DIAMOND DJ Status of CMV prevention and treatment in 2000. Hematoogyl 2000339-356.
42. LONGMATE JJ, YOURK J, LA ROSA C Population coverage by HLA Class I restricted CTL epitopes. Immimogenetlcs December 2000 (In press - online at http//link.springer.de/link/service/joumals/00251/content s/00/00271/papers/s002510000271chll0.htlm).
43. DIAMOND DJ, YORKJ, SUN J-Y, WRIGHT CL, FORMAN SJ Development of a candidate HLA A 0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood (.1997) 901751-1767.
44. BENMOHAMED L, KRISHNAN R, LONGMATE J et al. Induction of CTL réponse by a minimal cpitopc vaccine in HLA A'0201/DKl transgenic mice dependence on HIA class II restricted TH response. Human Immunol. (2000) 61764-779.
45. VITIELLO A, ISHIOKA G, GREY HM et at. Development of a lipopeptidc-bascd therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. (1995) 95341-349.
46. LIVINGSTON B, CRIMI C, GREY H et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. (1997) 1591383-1392.
47. LIVINGSTON B, ALEXANDER J, CRIMI C et al Altered T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans./ Immunol. (1999) 1623088-3095.
48. BAXBY D, PAO LETT! E Potential use of nonrcplicating vectors as recombinant vaccines. Vaccine(.1992) 108-9.
49. FRIES LF, TARTAGLIA J, TAYLOR J et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine an alternative poxvirus vector system. Vaccine (1996) 14428-434.
50. PLOTKIN SA, CADOZ M, MEIGNIER B et al. The safety and use of canarypox vectored vaccines. Dev. Biol. Stand. (1995) 84165-170.
51. GONCZOL E, BERENCSI K, PINCUS S et al Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovinis gh/coprotein B vaccine candidate. Vaccine (1995) 131080-1085.
52. KLEIN M, SCHOPPEL K, AMVROSSIADIS N, MACH M Strain-specific neutralization of human cytomegalovirus isolates by human sera. J. Virol. (1999) 73878-886.
53. WILLS MR, CARMICHAEL AJ, MYNARD K et al The human cytotoxic T-lymphocyte CCTL) response to cytomegalovinis is dominated by structural protein pp65 frequency, specificity and T-cell receptor usage of pp65-specific CTL. / Virol. (1996) 707569-7579.
54. WILLS MR, CARMICHAEL AJ, WEEKES MP et al Human virus-specific CDS CTL clones revert from CD45ROW8h to CD45RAWgh in vivo CD45RAW8l)CD8 T cells comprise both naive and memory cells. J. Immunol. (1999) 1627080-7087.
55. REUSSER P, RIDDELL SR, MEYERS JD, GREENBERG PD Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation pattern of recovery and correlation with cytomegalovirus infection and disease. Blooä (199D 781373-1380.
56. REUSSER P, CATHOMAS G, ATTENHOFER R, TAMM M, THIEHL G Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load./ Infect. Dis. (1999) 180247-253.
57. MCLAUGHLIN-TAYLOR E, FÄNDE H, FORMAN SJ et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CDS virus-specific cytotoxic T lymphocytes. J. Mcd. Virol. (1994) 43103-110.
58. BOPPANA SB, BRITT WJ Recognition of human Cytomegalovirus gene products by HCMV-speciflc cytotoxic T cells. Virology (1996) 222293-296.
59. ADLER SP, PLOTKIN SA, GONCZOL E et a!. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. (1999) 180843-846.
60. PIALOUX G, EXCLER JL, RIVIERE Y et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Human Retroviruses (1995) 11373-381.
61. BERNSTEIN DI.SCHLEISS MR, DICKEY M et al. Cytomegalovirus (CMV) vaccine evaluation using a canarypox vector expressing CMV gB and CMV gB subunit vaccine to prime and boost. Annual Meeting of Infectious Disease Society of America, New Orleans, LA, Sept. 7-10, 2000. Abstract 64l.
62. BERENCSIK, GYULAI ZS, GONCZOL E et al. A canarypox vector expressing cytomegalovirus phosphoprotein 65 (pp65) induces long-lasting cytotoxic T cell responses hi HCMV seronegative volunteers. / Infect. Dis. (2001) 1831171-1179.
63. BORYSIEWICZ LK, HICKLING JK, GRAHAM S et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kDa immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. / Exp. Med. (1988) 168919-931.
64. KERN F, SUREL IP, FAULHABER N étal. Target structures of the CD8 -T-ccll response to human cytomegalovirus the 72-kilodalton major immediate-early protein revisited./ Virol. (1999) 738179-8184.
65. ROBINSON HL, FELTQUATE DM, MORIB MJ DNA vaccines a new approach to immunization. In Vaccines. Brown F, Chanock R, Ginsberg H (Eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1995)69-75.
66. MARTINS LP, LAU IX, ASANO MS, AHMED R DNA vaccination against persistent viral infection. / Virol. (1995) 692574-2582.
67. DONELLY JJ, ULMER JB, SHIVER J\V, LIU MA DNA vaccines. Annu. Rev. Immunol. (1997) 15617-618.
68. BARRY MA, JOHNSTON SA Biological features of genetic immunization. Vaccine (1997) 15788-791.
69. LEITNER \VW, YING H, RESTIFO NP DNA and RNA-based vaccines principles, progress and prospects. Vaccine (2000) 18765-777.
70. HWANG ES, KWON KB, PARK JW, KIM DJ, PARK CG, CHA CY Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice. Mlcrobiol. Immunol. (1999) 43307-310.
71. ENDRESZ V, KARI L, BERENCSI K et al Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB>spccific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine (1999) 1750-58.
72. ENDRESZ V, BURIAN K, BERENCSI K et al Optimization of DNA immunization against human cytomegalovirus. Vaccine (2001) (In press).
73. PANDE H, CAMPO K, TANAMACHI B, FORMAN SJ, ZAIA JA Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand.J. Infect. Dis. (1995) 99117-120.
74. GONZALES ARMAS JC, MORELLO CS, CRANMER LD, SPECTOR DH DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. (1996) 707921-7928.
75. MORELLO CS, CRANMER LD, SPECTOR DH Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J. Virol. (2000) 743696-3708.
76. PEPPERL S, MUNSTER J, MACH M, HARRIS JR, PLACHTER B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. (2000) 746132-6146.
77. TOPILKO A, MICHELSON S Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts. Res. Virol. (1994) 14575-82